Literature DB >> 23371008

Inflammatory bowel disease and systemic AA amyloidosis.

Prayman T Sattianayagam1, Julian D Gillmore, Jennifer H Pinney, Simon D J Gibbs, Ashutosh D Wechalekar, Janet A Gilbertson, Dorota Rowczenio, Philip N Hawkins, Helen J Lachmann.   

Abstract

BACKGROUND: Systemic AA amyloidosis is a recognised complication of inflammatory bowel disease. AA amyloidosis is a potential cause of end-stage renal failure and mortality but little is known of the natural history of this condition in inflammatory bowel disease.
METHODS: We evaluated the clinical phenotype, disease progression and outcome amongst 26 patients with inflammatory bowel disease and AA amyloidosis followed prospectively at a single center between 1989 and 2010.
RESULTS: Twenty-two patients had Crohn's disease and four had ulcerative colitis. Fistulae and abscesses occurred in ten cases, all of whom had Crohn's disease. Amyloidotic proteinuric renal dysfunction occurred in all of the cases. It resolved in five patients with well-controlled inflammation, but was progressive in all of the other patients. Fifteen patients reached end-stage renal disease after a median time of 6.3 years from development of renal dysfunction (by Kaplan-Meier estimate), six of whom subsequently proceeded to renal transplantation. There were five functioning grafts at census 0.8, 3.2, 4.2, 20.1 and 24.6 years after transplantation. One graft failed 14.5 years after renal transplantation because of amyloid recurrence in a patient with sustained chronic inflammatory activity.
CONCLUSIONS: AA amyloidosis remains a serious complication of both Crohn's disease and ulcerative colitis, and is characterized by proteinuric renal dysfunction that may resolve following suppression of inflammatory activity. Patient and graft survival are excellent in patients who undergo renal transplantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23371008     DOI: 10.1007/s10620-012-2549-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Amyloidosis in regional enteritis. A report of five cases.

Authors:  J L WERTHER; A SCHAPIRA; O RUBINSTEIN; H D JANOWITZ
Journal:  Am J Med       Date:  1960-09       Impact factor: 4.965

2.  Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease.

Authors:  A Fernández-Nebro; I Ureña; M V Irigoyen; R García-Vicuña
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

3.  Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital.

Authors:  I T Weterman; I Biemond; A S Peña
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

4.  Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998.

Authors:  A L Wester; M H Vatn; O Fausa
Journal:  Inflamm Bowel Dis       Date:  2001-11       Impact factor: 5.325

Review 5.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

Authors:  N Van Rooijen; A Sanders
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

6.  The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study.

Authors:  S Poole; D Walker; R E Gaines Das; J R Gallimore; M B Pepys
Journal:  J Immunol Methods       Date:  1998-05-01       Impact factor: 2.303

7.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

Authors:  Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

8.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors:  Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

9.  Prevalence of amyloid deposition in long standing rheumatoid arthritis in Iranian patients by abdominal subcutaneous fat biopsy and assessment of clinical and laboratory characteristics.

Authors:  G Hussein Alishiri; Ahmad Salimzadeh; Mohammad Bagher Owlia; Jafar Forghanizadeh; Roya Setarehshenas; Nasrin Shayanfar
Journal:  BMC Musculoskelet Disord       Date:  2006-05-15       Impact factor: 2.362

10.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  14 in total

1.  Hidradenitis Suppurativa: a lesser-known cause of AA amyloidosis.

Authors:  Ö Helvacı; G Güz; E Adışen; S K Cevher; G Güz
Journal:  Hippokratia       Date:  2020 Jan-Mar       Impact factor: 0.471

2.  Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases.

Authors:  A Cañas-Ventura; E Rodríguez; M Andreu; L Márquez
Journal:  Dig Dis Sci       Date:  2013-07-18       Impact factor: 3.199

3.  Digitally reinforced hematoxylin-eosin polarization technique in diagnosis of rectal amyloidosis.

Authors:  Basak Doganavsargil; Gulruh Emiroglu Buberal; Huseyin Toz; Banu Sarsik; Burcin Pehlivanoglu; Murat Sezak; Sait Sen
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 4.  Renal manifestations in inflammatory bowel disease: a systematic review.

Authors:  Karen van Hoeve; Ilse Hoffman
Journal:  J Gastroenterol       Date:  2022-07-14       Impact factor: 6.772

Review 5.  Small bowel amyloidosis.

Authors:  Milena Gould; Neda Zarrin-Khameh; Joseph Sellin
Journal:  Curr Gastroenterol Rep       Date:  2013-10

6.  Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis.

Authors:  Prabin Sharma; Rodrigo Aguilar; Omer Asif Siddiqui; Mark Abi Nader
Journal:  Ann Gastroenterol       Date:  2017-06-14

7.  Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study.

Authors:  Seona Park; Jaeyoung Chun; Kyung-Do Han; Hosim Soh; Kookhwan Choi; Ji Hye Kim; Jooyoung Lee; Changhyun Lee; Jong Pil Im; Joo Sung Kim
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

8.  The prevalence, characteristics, and determinants of anaemia in newly diagnosed patients with inflammatory bowel disease.

Authors:  Małgorzata Woźniak; Magdalena Barańska; Ewa Małecka-Panas; Renata Talar-Wojnarowska
Journal:  Prz Gastroenterol       Date:  2019-03-12

9.  Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.

Authors:  Fabian Schnitzler; Matthias Friedrich; Johannes Stallhofer; Ulf Schönermarck; Michael Fischereder; Antje Habicht; Nazanin Karbalai; Christiane Wolf; Marianne Angelberger; Torsten Olszak; Florian Beigel; Cornelia Tillack; Burkhard Göke; Reinhart Zachoval; Gerald Denk; Markus Guba; Christian Rust; Norbert Grüner; Stephan Brand
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

10.  Variation of amino acid sequences of serum amyloid a (SAA) and immunohistochemical analysis of amyloid a (AA) in Japanese domestic cats.

Authors:  Meina Tei; Kazuyuki Uchida; James K Chambers; Ken-Ichi Watanabe; Takashi Tamamoto; Koichi Ohno; Hiroyuki Nakayama
Journal:  J Vet Med Sci       Date:  2017-12-04       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.